A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)

NCT04365036 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

207

Enrollment

OTHER

Sponsor class

Conditions

NK/T Cell Lymphoma Nos

Interventions

DRUG: Toripalimab
DRUG: Pegaspargase
DRUG: Gemcitabine
DRUG: Oxaliplatin
RADIATION: Definitive intensity-modulated radiotherapy (IMRT)

Sponsor

Sun Yat-sen University